Taysha Gene Ther Rg
Clinical‑stage biotech developing AAV‑based therapies for rare CNS monogenic disorders, with a pipeline that includes TSHA‑101 for GM2 gangliosidosis to TSHA‑121 for CLN7. The company partners with UT Southwestern and Yale to accelerate translation.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 73
- HQ: Dallas
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.